Signal
FDA Grants Second Approval under the National Priority Voucher Pilot Program
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-26 17:38 UTCUpdated 2026-02-26 20:27 UTC
rss
fierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.
Score total
1.05
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly...
Fierce Pharma (All) · fiercepharma.com · 2026-02-26 20:27 UTC
FDA Grants Second Approval under the National Priority Voucher Pilot Program
fda_press_releases · fda.gov · 2026-02-26 17:38 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- fda_press_releases (1)
Top origin domains (this list)
- fiercepharma.com (1)
- fda.gov (1)